High-affinity immunoglobulin E receptor autoantibodies (Anti-FcεRI)

High-affinity immunoglobulin E receptor (FcεRI) autoantibodies are pathogenic IgG molecules that target the alpha subunit of the FcεRI receptor on mast cells and basophils (PMID: 8316001). These autoantibodies function by cross-linking the receptors, which triggers the release of histamine, leukotrienes, and cytokines without the need for an allergen (PMID: 10409156). This mechanism is the defining feature of Type IIb autoimmune chronic spontaneous urticaria (CSU), accounting for approximately 30-50% of cases (StatPearls: NBK538502). Clinically, patients with these autoantibodies often experience more severe symptoms and may show resistance to standard H1-antihistamine therapies (PMID: 31034514). While the autoantibodies themselves are the cause of the disease, therapeutic strategies often target the receptor they bind to or the signaling pathways they activate. For example, the anti-IgE antibody omalizumab reduces the density of FcεRI on the cell surface, thereby limiting the sites available for autoantibody binding (PMID: 14752544). Other treatments include immunosuppressants like cyclosporine to reduce autoantibody production and novel BTK inhibitors to block downstream signaling (PMID: 34166807). Diagnostic identification of these autoantibodies is typically performed using the basophil activation test (BAT) or the autologous serum skin test (ASST) (PMID: 29943454).

Other names

Anti-FcεRI IgGAutoantibodies to the alpha subunit of the high-affinity IgE receptorFcεRI-alpha autoantibodiesIgG anti-FcεRI

The primary mechanism involves the cross-linking of the alpha subunits of the high-affinity IgE receptor (FcεRI) by IgG autoantibodies, mimicking the effect of IgE-antigen complexes and leading to mast cell and basophil degranulation (PMID: 8316001). Therapeutic interventions like omalizumab sequester free IgE, which causes a compensatory downregulation of FcεRI expression on effector cells, reducing the potential for autoantibody-mediated activation (PMID: 14752544). Additionally, Bruton's tyrosine kinase (BTK) inhibitors are used to block the intracellular signaling cascade initiated by receptor cross-linking, effectively preventing the release of inflammatory mediators (PMID: 34166807).